Production (Stage)
Artiva Biotherapeutics, Inc.
ARTV
$1.95
-$0.03-1.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 251.00K | 2.60M | 29.26M | 32.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 251.00K | 2.60M | 29.26M | 32.75M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 251.00K | 2.60M | 29.26M | 32.75M |
| SG&A Expenses | 18.74M | 17.21M | 15.42M | 13.39M | 13.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.96M | 67.54M | 63.59M | 61.10M | 60.23M |
| Operating Income | -74.96M | -67.28M | -60.99M | -31.84M | -27.48M |
| Income Before Tax | -71.72M | -65.37M | -61.20M | -32.45M | -25.89M |
| Income Tax Expenses | -- | -- | 72.00K | 72.00K | 72.00K |
| Earnings from Continuing Operations | -71.72 | -65.37 | -61.28 | -32.53 | -25.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.72M | -65.37M | -61.28M | -32.53M | -25.97M |
| EBIT | -74.96M | -67.28M | -60.99M | -31.84M | -27.48M |
| EBITDA | -72.49M | -64.85M | -58.58M | -29.50M | -25.20M |
| EPS Basic | -24.41 | -40.82 | -54.99 | -40.08 | -32.18 |
| Normalized Basic EPS | -15.73 | -25.99 | -43.87 | -34.56 | -29.62 |
| EPS Diluted | -25.08 | -41.49 | -69.81 | -67.27 | -59.36 |
| Normalized Diluted EPS | -15.73 | -25.99 | -43.87 | -42.28 | -37.34 |
| Average Basic Shares Outstanding | 68.44M | 44.90M | 21.33M | 3.24M | 3.23M |
| Average Diluted Shares Outstanding | 68.44M | 44.90M | 21.33M | 9.40M | 9.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |